Xaliproden in preventing neurotoxicity of oxaliplatin in first-line metastatic colorectal cancer
Colorectal Neoplasms · Metastases
Enrolment: 879 · Results not recorded
Loading the evidence…
Drug · Serotonin 1a (5-HT1a) receptor agonist (AGONIST, direct interaction). ChEMBL comment: neurotrophic and neuroprotective activity; appears to mimic or stimulate synthesis of neurotrophins, stimulating neuronal differentiation and proliferation and inhibiting neuronal cell death. Binds competitively with high affinity (Ki 2.0 nM) to 5-HT1a receptors. ATC N07XX03.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Colorectal Neoplasms · Metastases
Enrolment: 879 · Results not recorded
Colorectal Neoplasms · Metastases
Enrolment: 620 · Results not recorded
Colorectal Neoplasms
Enrolment: 102 · Results not recorded
Alzheimer Disease
Enrolment: 1306 · Results not recorded
Alzheimer Disease
Enrolment: 1455 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Localised irradiation of a 4 cm ileal loop with 7 once-daily fractions of 5.6 Gy (radiation enteropathy), and localised heart irradiation with a single 18 Gy dose (radiation-induced heart disease)
Xaliproden raised circulating TGF-beta1 by about 300% and worsened radiation injury, increasing intestinal injury score, wall and subserosal thickening, collagen I and III and myeloperoxidase-positive cells while reducing mucosal surface area, and increasing cardiac myofibroblasts, wall stress and…
Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.